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Abstract: 
A recent phase 2 study of metastatic colorectal carcinoma (CRC) patients showed that 
mismatch repair gene status was predictive of clinical response to PD-1-targeting immune 
checkpoint blockade. Further examination revealed strong correlation between PD-L1 
protein expression and microsatellite instability (MSI) in stage IV CRC, suggesting that the 
amount of PD-L1 protein expression could identify late stage patients who may benefit from 
immunotherapy. To assess whether the clinical associations between PD-L1 gene 
expression and MSI identified in metastatic CRC are also present in stage II/III CRC, we 
used in silico analysis to elucidate the cell types expressing the PD-L1 gene. We found a 
significant association of PD-L1 gene expression with MSI in early stage CRC (P < 0.001) 
and show that unlike in non-CRC tumors, PD-L1 is derived predominantly from the immune 
infiltrate. We demonstrate  that PD-L1 gene expression has positive prognostic value in the 
adjuvant disease setting (PD-L1low v PD-L1high HR = 9.09; CI, 2.11–39.10). PD-L1 gene 
expression had predictive value, as patients with high PD-L1 expression appear to be 
harmed by standard-of-care treatment (HR = 4.95; CI,1.10-22.35). Building on the promising 
results from the metastatic CRC PD-1–targeting trial, we provide compelling evidence that 
PD-L1high/MSI/immunehigh stage II/III CRC patients should not receive standard 
chemotherapy. This conclusion supports the rationale to clinically evaluate this patient 
subgroup for PD-1 blockade treatment. 
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Introduction: 
Stroma-derived factors have long been known to influence cancer progression (1), and the 
importance of the microenvironment for molecular classification of colorectal cancer (CRC) 
tumors  has been confirmed (2, 3). These studies highlight the influence of the non-
neoplastic component of the tumor on patient prognosis. Expression of PD-L1, the immune 
checkpoint inhibitor, has been primarily detected on the surface of epithelial neoplastic cells 
in a number of cancers; however, in CRC, immunohistochemistry (IHC)-based studies of 
small cohorts have detected high PD-L1 expression in the stromal and immune 
compartments (4, 5).  Although upregulation of PD-L1 in the tumor microenvironment is a 
recognized tumor immune- defense mechanism, these findings suggest a different origin for 
PD-L1 protein expression in CRC.  
The mismatch repair system (MMR) helps preserve the fidelity of the genome (6, 7). CRCs 
which harbor defects in MMR demonstrate high microsatellite instability (MSI) and account 
for 12-15% of CRCs. MSI tumors are generally defined by their large number of somatic 
mutations, compared to microsatellite stable (MSS) tumors. These tumors also exhibit heavy 
peritumoral/intratumoral lymphocytic infiltration, most likely due to a large number of mutated 
antigenic epitopes at the cell surface; this has been previously correlated with good 
prognosis in early stage disease (8).  
A number of adjuvant trials have questioned the value of chemotherapy for defined CRC 
molecular subtypes in early stage disease, with some studies suggesting potential harm, 
particularly to the overall good prognosis MSI group (9). Although preclinical data inferred 
that MSI tumors would not respond to 5FU-based treatment (10), the first large adjuvant 
study published using MSI status to stratify patients revealed that patients with MSI tumors 
did benefit from addition of chemotherapy following surgery (11). However, 11 subsequent 
studies have shown no benefit from 5FU-based treatment for patients with MSI CRC in the 
adjuvant setting (9).  
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Recent clinical studies in melanoma, renal cell carcinoma, and non–small cell lung cancer 
have reported significant positive responses to PD-1 checkpoint targeting (12). In contrast, 
results in CRC have been disappointing (12). Interrogation of factors associated with 
response to PD-1 blockade suggested that MSI status was a predictor of response, 
underpinning a phase 2 clinical trial (13) in patients with metastatic CRC stratified by MSI 
status. The disease control rate in this study was 90% (CI: 55-100) for patients with MSI 
tumors and 11% for patients with MSS tumors (CI: 1-35), supporting the hypothesis of strong 
predictive value of MSI status for positive response to PD-1 blockade in advanced CRC. In 
addition, many CD8+ infiltrating T lymphocytes were detected at the invasive front regions of 
these tumors, corresponding to increased PD-L1 expression levels at the tumor margin. 
Effective use of PD-1–targeting checkpoint inhibitors requires reliable biomarkers/companion 
diagnostics. Immuohistochemical detection of PD-L1 is currently confounded by technical 
variation, fluctuations in detection levels, and reproducible cut-off thresholds. Most 
importantly, marked intratumoral staining heterogeneity greatly hinders reproducibility of 
immunohistochemical scoring systems. Thus, alternative approaches for assessing PD-L1 
are required.  
The extremely promising results in stage IV disease prompted us to evaluate the potential 
for immune checkpoint–targeting in the adjuvant setting. We performed extensive 
bioinformatics analyses employing well-characterized independent transcriptional profiling 
datasets to determine (i) whether PD-L1 gene expression is associated with specific cell 
lineage compartments within the CRC tumor microenvironment; (ii) ability to stratify patients 
in early stage CRC using PD-L1 gene expression and determine its association with MSI 
status/immune infiltration; and (iii) clinical relevance of PD-L1 gene expression to both 
prognosis and potential for benefit from adjuvant chemotherapy.  
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Materials and Methods 
 
Independent datasets 
Gene expression profiles from independent CRC datasets were downloaded from NCBI 
Gene Expression Omnibus (GEO) (http://www.ncbi.nlm.nih.gov/geo/) under accession 
numbers GSE14333, GSE35602, GSE13294, GSE39396 and GSE39582. GSE14333 
contains microarray profiles of surgically resected specimens in 290 CRC patients; 185 have 
additional treatment and survival data and are employed in this study. GSE35602 contains 
microarray profiles separately profiled from micro-dissected stroma or epithelium regions 
from thirteen CRC tissues. GSE13294 contains 155 CRC microarray profiles, with MSI 
status, from surgically resected specimens. GSE39396 contains microarray profiles from 
fresh colorectal specimens where FACS has been used to divide cells into specific 
endothelial (CD45+EPCAM–CD31–FAP–), epithelial (CD45– EPCAM+CD31–FAP–), leukocyte 
(CD45–EPCAM–CD31+FAP–) and fibroblast (CD45–EPCAM–CD31–FAP+) populations prior to 
microarray profiling. GSE39582 contains 566 stage I-IV profiles from a large CRC series, of 
which the stage II/III profiles were selected for analysis. 
Transcriptional analysis 
Partek Genomics Suite was used for independent dataset analysis. For the purpose of 
clustering, data matrices were standardized to the median value of probe sets expression. 
Standardization of the data allows for comparison of expression levels for different probe 
sets. Following standardization, 2-dimensional hierarchical clustering was performed 
(samples x probe sets/genes). Euclidean distance was used to calculate the distance matrix, 
a multidimensional matrix representing the distance from each data point (probe set-sample 
pair) to all the other data points. Ward’s linkage method was subsequently applied to join 
samples and genes together, with the minimum variance, to find compact clusters based on 
the calculated distance matrix.  
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Statistics 
Median and tertile stratification was performed on GSE13294 by calculation of mean 
expression values from both CD274 probe-sets. These values were then classified as high 
and low based on 77:78 sample distributions or as high, medium, and low based on 
52:51:52 sample distributions. Student t tests and Fishers exact tests were carried out using 
GraphPad Prism version 5 for Windows, GraphPad Software.  
Survival analysis 
Survival curves, comparing expression and treatment subgroups were estimated with the 
Kaplan–Meier method and compared by the log-rank test, using GraphPad Prism version 5 
for Windows, GraphPad Software. Cox Proportional Hazards analysis, using Stata version 
11.2, was applied to evaluate recurrence-free survival according to PD-L1 gene expression 
levels within the indicated subgroups, prior to and after adjustment for age, sex, tumor stage 
and location, and receipt of adjuvant treatment. Categorical and continuous variables were 
compared between individuals within the overall cohort and also in PD-L1high/MSI versus PD-
L1low/MSS tumors using chi-squared tests and t-tests, respectively.  
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Results: 
PD-L1 gene expression associated with immune component of TME 
Unlike other cancers, PD-L1 expression in the colorectal tumor microenvironment (TME) 
may not be exclusive to epithelial tumor cells (4). To further investigate this preliminary 
finding, we utilized 2 CRC gene expression transcriptomic datasets, derived from samples 
either laser-microdissected to purify stromal and epithelial regions (GSE35602), or 
separated into epithelial, leukocyte, endothelial or fibroblast components using FACS 
(GSE39396) prior to microarray profiling of the separated cells. Scatterplot and boxplot 
assessment of gene expression levels of PD-L1 (CD274), according to region of origin, 
revealed significantly increased gene expression in the stroma compared to neoplastic 
epithelial cells in the laser-microdissected dataset (two-tailed Student t-test P < 0.0001, Fig. 
1A and C).  In the FACS-derived microarray dataset, significantly higher levels of PD-L1 
gene expression were observed in tumor-associated leukocytes compared to epithelial cells 
(two-tailed Student t-test P = 0.0071, Fig. 1B and D).  
In order to assess the purity of the microdissection of the samples from the GSE35602 
dataset, we utilized a previously published gene expression list derived exclusively from non-
epithelial cells. These 213 genes were defined from 3 signatures specifically expressed by 
cancer-associated fibroblasts (CAFs) (n = 131), leukocytes (n = 47) and endothelial cells (n 
= 35) (3). Using hierarchical clustering and principal component analyses, we robustly 
identified 2 distinct groups in the GSE35602 dataset that corresponded to each “region of 
origin” with 100% accuracy (Supplementary Fig. S1A and C). When the same approach was 
applied to GSE39396 (FACS-sorted dataset), region of origin was again identified with 100% 
accuracy (Supplementary Fig. S1B and D).  
In addition to PD-L1, expression of other immune therapy targets (CTLA4, LAG3, and IDO1) 
has also been reported to be upregulated in immune infiltrating cells of MSI tumors 
compared to MSS tumors(4), although their gene expression levels in individual cell 
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compartments have not been assessed. Using region-specific and cell-specific gene 
expression profiles, we found CTLA4 (6.3 fold, P < 0.001), LAG3 (4.5 fold, P < 0.001), PD-L1 
(4.2 fold, P < 0.001), and IDO1 (9.2 fold, P < 0.001) are all elevated in stroma compared to 
epithelium in CRC tumor samples (Fig. 1D). Whereas IDO1 expression was elevated in all 
stromal compartments compared to epithelial cells, the elevated expression of CTLA4, 
LAG3, and PDL1 was confined to the leukocyte-specific compartment (Fig. 1E and F). We 
also confirm that expression of interferon-γ (IFNG) is specific to the immune-derived 
compartment (Supplementary Fig. S1E), consistent with previous findings (14). 
Collectively, these analyses provide compelling evidence that PD-L1 in colorectal tumors is 
predominantly derived from infiltrating immune cells rather than neoplastic epithelial cells. 
 
Association between MSI, immune infiltration, and PD-L1 gene expression 
To assess whether the clinical associations between PD-L1 gene expression and MSI 
identified in metastatic CRC are also present in stage II/III CRC, we evaluated transcriptomic 
data derived from a cohort of 155 patients (GSE13294), enriched to contain approximately 
equal numbers of MSI (n = 78) and MSS (n = 77) tumors. Using a median- and tertile-
stratification approach based on mean PD-L1 gene expression, we differentiated samples 
based on high or low PD-L1 gene expression (Fig. 2A) and high, medium, or low gene 
expression (supplementary Fig. S2A). Using a median-stratified approach, PD-L1 gene 
expression is significantly associated with MSI status (Fishers exact two-tailed test P < 
0.0001, Fig. 2B). In addition, this PD-L1high/MSI-rich subgroup is significantly associated with 
the 47 leukocyte-specific non-epithelial gene signature (Fishers exact two-tailed test P < 
0.0001, Fig. 2C)). When the intermediate group (n = 51) is removed from the tertile analysis, 
we again find a significant correlation between PD-L1 gene expression and both MSI and the 
leukocyte-specific signature (Supplementary Fig. 2B, C, and D) These results reveal the 
 Dunne PD 
Page | 9 
 
relationship between high PD-L1 gene expression, MSI, and immune infiltration in stage II/III 
disease. 
 
Identification of a subgroup of patients with high PD-L1 gene expression 
Utilizing hierarchical clustering of microarray gene expression profiles from a large stage II/III 
CRC dataset (GSE39582), and employing Euclidean and Ward metrics, we identified a 
distinct subgroup of patients with high PD-L1 gene expression relative to the remaining 
population (Fig. 3A). This PD-L1high subgroup accounted for 20% of the overall cohort, which 
we use as our threshold for all subsequent analyses; further investigation highlighted a 
strong correlation between elevated PD-L1 gene expression and MSI genotype (Fishers 
exact two-tailed test P < 0.0001; Fig. 3A and B, Supplementary Fig. S3A), further validating 
our earlier findings (Fig. 2).  
Stratification of the data was performed to facilitate an evaluation of the available 
clinicopatholologic factors using two different comparisons; PD-L1high gene expression 
subgroup (PD-L1high) versus PD-L1low gene expression subgroup (PD-L1low) in the entire 
cohort and MSI versus MSS in the PD-L1high subgroup only.  Within the entire cohort, 
individuals with PD-L1high tumors did not differ from those with PD-L1low tumors in terms of 
age, sex or stage distribution. PD-L1high tumors were less likely to be treated with adjuvant 
chemotherapy, although this did not reach statistical significant (P = 0.07). PD-L1high tumors 
were more likely to be right-sided, MSI, CpG island methylator phenotype (CIMP) positive, 
chromosome instability (CIN) negative, and protein kinase BRAF mutant than PD-L1low 
tumors, but not p53 or KRAS mutant (Table 1).   
Findings from the PD-L1high subgroup stratified by MSI or MSS, confirm that MSS/PD-L1high 
tumors were less likely to be right-sided, CIMP+, CIN– and BRAF mutant than MSI/PD-L1high 
tumors This analysis again highlighted that whereas MSI status is significantly associated 
with high PD-L1 gene expression, a subgroup of 13% of MSS tumors were also classified as 
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PD-L1high. Utilizing the previously described leukocyte-specific signature (3) that is solely 
attributed to the leukocyte compartment of the TME, we found strong overlap between those 
patients in the PD-L1high subgroup and those with a gene expression profile indicative of an 
increased immune infiltrate (Fishers exact two-tailed test P < 0.001, Fig. 3C). This finding 
further confirmed that the PD-L1high subgroup, which is significantly enriched for MSI (P < 
0.001), was also associated with more tumor-infiltrating immune cells, and highlights PD-L1 
expression as a robust transcriptional marker for this subgroup. Although we do find 
significant clinicopathological differences between MSI and MSS in the PD-L1high subgroup, 
in agreement with our data presented in Figs. 1 and 2, it is the biological signature indicative 
of a large immune infiltration that appears to dictate the level of PD-L1 gene expression. 
Further analysis confirmed co-expression and elevated expression of CTLA4, LAG3, and 
IDO1 in stage II/III tumors samples that have high expression of PD-L1 (Supplementary Fig. 
S3B), in addition to significant upregulation of IFNγ (two-tailed Student t-test P < 0.001, 
Supplementary Fig. S3C). 
 
PD-L1 is a significant positive prognostic marker in early stage disease 
To investigate the clinical relevance of PD-L1 gene expression, we used relapse follow-up 
data associated with the well-characterized GSE39582 dataset. Patients (n = 201) were 
stratified based on PD-L1 subgroup, stage and treatment. In the untreated stage III 
population, we found a clear difference in relapse-free survival (RFS) between low and high 
PD-L1 subgroups, with the PD-L1low subgroup having a significantly worse outcome (P = 
0.0003; HR = 9.09; 95% CI, 2.11–39.10; Fig. 4A and B; Table 2). However, in the treated 
cohort, the correlation between survival and high PD-L1 expression was lost (P = 0.6514; 
HR = 0.86; 95% CI, 0.45–1.66), suggesting that PD-L1 gene expression also has value for 
predicting benefit from standard adjuvant chemotherapy (Fig. 4B, Table 2).  
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To address this question, we performed treatment interaction analyses and found that, 
whereas patients with low expression of the PD-L1 gene significantly benefit from adjuvant 
chemotherapy (P = 0.0062; HR = 0.49; 95%CI, 0.29–0.83), patients in the PD-L1high 
subgroup have poorer overall survival following treatment (P = 0.0208; HR = 4.95; 95%CI, 
1.10–22.35; Fig. 4A and B; Table 2). An adjusted analysis for the known confounders and 
covariates of PD-L1 gene expression (Table 1) again confirmed that PD-L1 gene-expression 
could be considered as an independent biomarker for patient stratification, as although the 
prognostic and predictive trend remained the same, the adjusted multivariate significance 
was lost (Table 2). 
In order to confirm these findings in an independent patient cohort, we interrogated a further 
early stage CRC dataset (GSE14333). Patients (n = 185) were again stratified into high and 
low PD-L1 subgroups in similar proportions as identified using our initial dataset. In Dukes’ B 
patients within this cohort, high PD-L1 gene expression was significantly associated with 
better disease-free survival (DFS) in the untreated population compared to those who 
received adjuvant treatment (P = 0.0371; HR = 10.18; CI, 1.15–90.14). This trend was also 
observed in the combined Dukes B/C cohort, but failed to reach significance, most likely due 
to the small number of patients in this combined cohort compared to the original dataset 
(Fig. 4C).  
These data indicate that TME-derived PD-L1 transcription levels are both a positive 
prognostic marker for improved relapse/disease-free survival in early stage disease, but 
importantly also are a negative predictive marker for chemotherapy in the adjuvant setting.  
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Discussion: 
Since the FDA’s approval of the first immune checkpoint therapy (the CTLA4-specific 
antibody ipilimumab), a number of clinical trials have demonstrated the potential for targeting 
this pathway in a variety of cancers. However, immune therapy has had surprisingly little 
impact in CRC. A recent phase 2 study gave the first indication that PD-1 targeting of CRC in 
metastatic disease significantly benefited patients with MSI tumors when compared to those 
with MSS disease (13). This study also indicated that PD-L1 expression (assessed by IHC) 
was strongly associated with MSI, suggesting that expression of PD-L1 may be a useful 
predictive biomarker of response to PD-1 immune checkpoint-targeting in this setting.  
Using an in silico approach, we assessed whether PD-L1 gene expression was associated 
with MSI in early stage CRC, which would provide a rationale for pursuing PD-1 checkpoint-
targeting in the adjuvant disease setting. We found that PD-L1 transcription levels are 
significantly elevated in the immune cells present in the TME, in agreement with an earlier 
study in a small patient cohort (4). Given that high immune infiltration can occur in CRC, 
these findings may explain the difference in response rates to immune-checkpoint targeting 
in CRC compared to other tumors, e.g. lung, melanoma, where PD-L1 expression has been 
detected in the membrane of epithelial neoplastic cells. Using a transcriptomic dataset from 
a 155 CRC patient cohort, enriched to include ~50% MSI/MSS, we found that PD-L1high 
tumors are significantly associated with the MSI genotype. Additionally, a significant 
correlation between high PD-L1 gene expression and substantial immune cell infiltration was 
found, further supporting the hypothesis that these patients would benefit from PD-1–
targeting agents. This significant association with MSI was also evident in a large well 
characterized stage II/III clinical cohort, which also confirms that PD-L1 gene expression is 
significantly associated with right-sided, CIMP and BRAF mutant tumors. 
A recent metastatic CRC clinical trial uncovered a subgroup of patients with MSI genotype 
and high PD-L1 levels using IHC; we identified a distinct subgroup of stage II/III CRCs, this 
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time identifiable by high PD-L1 transcription levels. While this subgroup was significantly 
associated with MSI, it was not exclusive to this genotype, with a small number of MSS 
tumors also being PD-L1high. Conversely, a small proportion of MSI patients were classified 
as PD-L1low. These results suggest that while the MSI genotype results in high mutation 
rates which promote high levels of immune infiltration, the expression of PD-L1, and indeed 
immune infiltration levels, can also be upregulated by MSI independent mechanisms. Thus, 
PD-L1 gene expression rather than MSI status may be a more powerful predictive biomarker 
for response to PD-1/PD-L1 checkpoint inhibition in CRC. Previous studies have shown that 
patients with MSI CRC generally have a good overall prognosis in early stage disease, 
however there is still debate as to the benefit of adjuvant chemotherapy in this group (9). 
Recently, a large meta-analysis concluded that there was no effect of adjuvant treatment for 
MSI patients, whereas there was a significant benefit in MSS patients (15). Data presented 
here show for the first time that high PD-L1 transcription levels, which is significantly 
associated with the MSI genotype, identify a subgroup of patients with a significantly better 
prognosis in early stage disease. In addition, we also show that this PD-L1high subgroup 
derives no clinical benefit and indeed may be harmed by adjuvant 5-FU-based 
chemotherapy using an unadjusted analysis.  
 
Although this dataset, and the independent validation set, were not generated from material  
collected for randomized control trials, nonetheless, our findings on high PD-L1 
transcriptional levels have clinical implications above and beyond MSI status alone, for 
further stratifying patients into those likely to benefit from standard adjuvant chemotherapy 
and those who may potentially be harmed. Our analyses suggest that the PD-L1high 
subgroup should not be given adjuvant 5-FU based chemotherapy following surgery, 
whereas patients with low PD-L1 gene expression significantly benefit from adjuvant 
treatment, in both unadjusted and adjusted models for survival analysis. Moreover, although 
data presented here strongly indicate that PD-L1high patients may not need any systemic 
therapy, their PD-L1 levels, MSI status, and immune infiltrate levels confirm that it is this 
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clinical subgroup, (based on the recent clinical trial in the metastatic setting), which may 
instead benefit from PD-1/PD-L1 immune checkpoint inhibitors, notably in stage III disease. 
This PD-L1high subgroup also displayed increased expression of a number of other 
immunotherapy targets, namely CTLA4, LAG3, and IDO1. Similar to the findings presented 
here for PD-L1, expression of each of these targets is confined to the stroma, in particular to 
the immune compartment, with the exception of the metabolic regulator IDO1, which is found 
in all stromal compartments. These findings highlight the potential for combination 
immunotherapies in this immune checkpoint overexpressing subgroup. Although PD-L1 
gene expression had significant prognostic and predictive value in 2 independent cohorts, 
final validation requires transcriptional data, detailed treatment information, and clinical 
follow up from an independent, well-balanced cohort, enriched for MSI stage II/III CRC 
patients enrolled in a prospective clinical trial. This type of patient stratification approach is 
ongoing in current clinical trials (16, 17) that will enable further biomarker-based validation in 
this setting. Ongoing debate surrounds the definition of a clinically relevant companion 
diagnostic threshold for assessing PD-L1 protein levels by IHC, to predict benefit from PD-1 
blockade. This will only be possible by retrospective outcome-supervised analysis of the 
tumor tissue from ongoing and completed PD-1/PD-L1 checkpoint inhibition trials in CRC. 
Matched IHC and microarray profiling from the same tissue would allow the generation of 
these urgently required thresholds for prospective use. 
 
The transcriptional profiles we have analyzed are representative of primary CRC tumors 
prior to therapy, and as such provide insight into the cell populations present and their 
signaling activities during development of the primary tumor. It is conceivable that the 
majority of these tumors, which we now show have a paucity of immune cells, initiate and 
develop by circumventing a widespread immune response (18). It is only tumors that have 
escaped immunosurveillance, allowing development of invasive malignancy and subsequent 
metastatic spread, which have high relapse rates and poor survival. The small proportion of 
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tumors that we have identified with an inherently large immune infiltrate [resulting from high 
numbers of mutated antigenic epitopes due to their MSI status,(8)] can be held in a state of 
equilibrium by this response (19), despite PD-L1–mediated immune checkpoint activation. 
This may explain why these tumors have a relatively good prognosis if left untreated (9). In 
the post-treatment setting, we know that addition of 5-FU based adjuvant therapy following 
surgery results in loss of tumor infiltrating immune cells (20). Thus, patients with immune-rich 
tumors would be harmed by exposure to 5-FU, therefore explaining the negative predictive 
value between high PD-L1 transcription and response to standard-of-care chemotherapy.     
In conclusion, data presented here, alongside data from the metastatic trial (13) identify a 
subgroup that is defined by an underlying biology consisting of increased PD-L1 
transcription, MSI genotype, and large immune infiltrates in stage II/III disease. We now 
demonstrate the prognostic value of PD-L1 gene expression in early stage CRC and 
highlight the potentially harmful effects of standard-of-care chemotherapy in this clinically 
relevant and PD-L1–definable subgroup.  
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Figure Legends 
Figure 1: PD-L1 gene expression is higher in the stromal immune compartment of the 
tumor microenvironment. A. Scatterplot indicating higher PD-L1 gene expression in 
stromal cells compared to the epithelium of 13 microdissected primary tumor samples 
(GSE35602). B. PD-L1 gene expression was higher in the leukocyte population compared to 
fibroblast, endothelial, and epithelial populations isolated by FACS (GSE39396). C + D. Dot 
plot with associated box and whisker plots representing the mean expression values for PD-
L1 in each sample set. 10% lower and 90% upper values are indicated. E + F. Euclidean 
clustering for gene expression profiles of CTLA4, LAG3, PD-L1, and IDO1 in each sample 
set. Overlay bar indicates the region- or cell-of-origin as used in A–D. 
Figure 2: Association of high PD-L1 gene expression with MSI subtype and 
substantial immune infiltrate. A. (Left) Dot plot with associated box plots representing the 
mean gene expression values for PD-L1 in each subgroup. (Right) uniform probability plot of 
PD-L1 expression values highlight the cutoff between PD-L1high and PD-L1low subgroups 
(GSE13294)  B + C. (Left) Dot plot with associated box plots in PD-L1high  and PD-L1low 
subgroups further stratified by MSI status (B) and immune infiltrate signature (C). (Right) 
Fishers exact two-tailed test confirms a statistically significant correlation between high PD-
L1 levels and either MSI status (B) or immune infiltrate signature (C). Whiskers on boxplots 
represent 10% lower and 90% upper values. 
Figure 3: PDL1 gene expression profile in stage II/III CRC. A. (Left) Hierarchical 
clustering of stage II/III CRC patient cohort (GSE39582) based on expression profiles of 
PDL1 (CD274) identifies a strong positive subgroup accounting for 20% of the overall 
population. Overlay bar indicates assigned PD-L1 subgroup (PD-L1high, red; PD-L1low, blue) 
and MSI/MSS status (MSI, black; MSS, gray; NA, white). (Right) Scatterplot of PD-L1 gene 
expression values highlight the positive and negative groups identified in the heatmap. B. 
(Left) Scatterplot of PD-L1 gene expression values according to MSI/MSS status. (Right) 
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Fishers exact test confirms a statistically significant correlation between high PDL1 transcript 
amounts and MSI status. C. Hierarchical clustering of patient cohort based on leukocyte-
specific gene signature stratifies population into 3 groups based on their immune infiltrate 
content. Overlay bar indicates that the high immune infiltrate subgroup overlaps strongly with 
the high PDL1 gene expression subgroup. 
Figure 4: PD-L1 expression is a strong positive prognostic and negative predictive 
marker to chemotherapy in CRC. A. Survival curve using Kaplan-Meier estimation 
comparing PD-L1 transcript expression in untreated tumors (left) and comparing treated  and 
untreated for PD-L1high (right) stage III CRC patients (GSE39582). B. Unadjusted hazard 
ratio analysis of the cohort based on PD-L1 expression and/or receipt of adjuvant treatment. 
Hazard ratio is plotted on a logarithmic base 10 scale. C. Further confirmation of prognostic 
and predictive value for PD-L1 transcription in Dukes B (left) and combined Dukes B/C 
(right) in GSE41333.  
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PD-L1 Low v High – Full cohort 
PD-L1 Low v High - Untreated 
PD-L1 Low v High - Treated 
Treated v Untreated - PD-L1high 
Treated v Untreated - PD-L1low 
  All colon cancers   PD-L1high only    
Characteristic PD-L1low 
n = 340 
PD-L1high 
n = 84 
P value MSI 
n = 36 
MSS 
n = 48 
P value 
  
Age, years, mean (SD) 
  
67.6 (12.7) 
  
69.5 (13.9) 
  
0.23 
  
70.8(17.0) 
  
68.6 (11.2) 
  
0.47 
Sex, n (%) 
  Male 
  Female 
  
193 (56.8) 
147 (43.2) 
  
49 (58.3) 
35 (41.7) 
  
  
0.80 
  
19 (52.8) 
17 (47.2) 
  
30 (62.5) 
18 (37.5) 
  
  
0.37 
Tumour stage, n (%) 
  II 
  III 
  
181 (53.2) 
159 (46.8) 
  
41 (48.8) 
43 (51.2) 
  
  
0.47 
  
19 (52.8) 
17 (47.3) 
  
22 (45.8) 
26 (54.2) 
  
  
0.53 
Tumour location, n (%) 
  Proximal 
  Distal 
  
125 (36.8) 
215 (63.2) 
  
54 (64.3) 
30 (35.7) 
  
  
<0.001 
  
32 (88.9) 
4   (11.1) 
  
22 (45.8) 
26 (54.2) 
  
  
<0.001 
Adjuvant treatment* 
receipt, n (%) 
  No 
  Yes 
  
178 (52.4) 
161 (47.4) 
  
54 (64.3) 
29 (34.5) 
  
  
0.07 
  
27 (75.0) 
8   (22.2) 
  
27 (56.3) 
21 (43.8) 
  
  
0.07 
MSI status, n (%) 
  MSI 
  MSS 
  
27    (7.9) 
313 (92.1) 
  
36 (42.9) 
48 (57.1) 
  
  
<0.001 
  
  
/ 
  
  
/ 
  
  
/ 
CIMP, n (%) 
  Negative  
  Positive 
  Unknown 
  
246 (72.4) 
40   (11.8) 
54   (15.9) 
  
41 (48.8) 
30 (35.7) 
13 (15.5) 
  
  
  
<0.001 
  
11 (30.6) 
22 (61.1) 
3   (8.3) 
  
30 (62.5) 
8   (16.7) 
10 (20.8) 
  
  
  
<0.001 
CIN, n (%) 
  Negative  
  Positive 
  Unknown 
  
50   (14.7) 
218 (64.1) 
72    (21.2) 
  
27 (32.1) 
41 (48.8) 
16 (19.1) 
  
  
  
0.001 
  
22 (61.1) 
11 (30.6) 
3   (8.3) 
  
5   (10.4) 
30 (62.5) 
13 (27.1) 
  
  
  
<0.001 
p53, n (%) 
  WT  
  MT 
  Unknown 
  
100 (29.4) 
131 (38.5) 
109 (32.1) 
  
33 (39.3) 
26 (31.0) 
25 (29.8) 
  
  
  
0.20 
  
15 (41.7) 
3   (8.3) 
18 (50.0)** 
  
18 (37.5) 
23 (47.9) 
7   (14.6)** 
  
  
  
<0.001** 
KRAS, n (%) 
  WT  
  MT 
  Unknown 
  
194 (57.1) 
128 (37.7) 
18    (5.3) 
  
53 (63.1) 
28 (33.3) 
3   (3.6) 
  
  
  
0.56 
  
25 (69.4) 
10 (27.8) 
1   (2.8) 
  
28 (58.3) 
18 (37.5) 
2   (4.2) 
  
  
  
0.58 
BRAF, n (%) 
  WT  
  MT 
  Unknown 
  
278 (81.8) 
18   (5.3) 
44   (12.9) 
  
55 (65.5) 
19 (22.6) 
10 (11.9) 
  
  
  
<0.001 
  
18 (50.0) 
17 (47.2) 
1   (2.8) 
  
37 (77.1) 
2   (4.2) 
9   (18.8) 
  
  
  
<0.001 
MSI: Microsatellite instability; MSS: Microsatellite stable; MT: Mutant; WT: Wild-type. 
*Adjuvant chemotherapy treatment receipt, unknown for 2 individuals (one PDL-1high, one PDL-1low). 
** p53 results confounded by lack of information for mutational status in 50% of PD-L1high MSI cases 
Table 1 
Table 1: Characteristics of colon cancer patients and tumours 
according to PD-L1 gene expression status. 
  Unadjusted Adjusted* 
Entire cohort PD-L1 Low v High HR 1.64 (95% CI 0.91-2.97) HR 1.32 (95% CI 0.69-2.54) 
Untreated Only PD-L1 Low v High  HR 9.09 (95% CI 2.11-39.10)  HR 4.81 (95% CI 0.79-29.19)  
Treated Only PD-L1 Low v High  HR 0.86 (95% CI 0.45-1.66) HR 0.80 (95% CI 0.40-1.60)  
PD-L1High Only Treated v Untreated  HR 4.95 (95%CI 1.10-22.35) HR 1.62 (95%CI 0.25-10.36)  
PD-L1Low Only Treated v Untreated  HR 0.49 (95%CI 0.29-0.83)  HR 0.44 (95%CI 0.25-0.80) 
* Adjusted for all confounders in Table 1, with those that were significant at P < 0.25 level kept in the 
model as covariates. PD-L1 results adjusted for age, sex, CIMP, CIN, and KRAS. Tested for tumour 
location, BRAF, MSI, and p53. 
Table 2 
Table 2: Unadjusted and adjusted analyses of relapse-free survival.  RFS analysis 
was performed using Cox proportional hazards method stratified by PD-L1 levels or 
treatment expression levels. Analysis was performed both before and following 
adjustment.  
